Original Research

Published on 25 Nov 2022

Emerging current trends and research focus related to pancreatic cancer metabolism: A bibliometric and visualized analysis

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Qian Shen
Chuanlong Zhang
Xiaochen Jiang
Junchen Li
Fudong Liu
Xiyuan Zhang
Ge’er En
Bo Pang

Frontiers in Oncology

doi 10.3389/fonc.2022.1009700

3,486 views
2 citations

Original Research

Published on 25 Nov 2022

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Jin-Kai Feng
Zong-Han Liu
Zhi-Gang Fu
Zong-Tao Chai
Ju-Xian Sun
Kang Wang
Yu-Qiang Cheng
Hong-Fei Zhu
Yan-Jun Xiang
Li-Ping Zhou

Frontiers in Oncology

doi 10.3389/fonc.2022.954203

2,870 views
7 citations

Review

Published on 24 Nov 2022

The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Bing-Qing Li
Xin-Yuan Liu
Tao Mao
Tao-Hua Zheng
Peng Zhang
Qi Zhang
Yu Zhang
Xiao-Yu Li

Frontiers in Oncology

doi 10.3389/fonc.2022.1050274

2,577 views
2 citations

Original Research

Published on 24 Nov 2022

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Yong Yi
Bao-Ye Sun
Jia-Lei Weng
Cheng Zhou
Chen-Hao Zhou
Ming-Hao Cai
Jing-Yun Zhang
Hong Gao
Jian Sun
Jian Zhou

Frontiers in Oncology

doi 10.3389/fonc.2022.1046584

2,760 views
13 citations

Methods

Published on 24 Nov 2022

Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Guangxin Li
Bin Shu
Zhuozhao Zheng
Hongfang Yin
Chen Zhang
Ying Xiao
Yanmei Yang
Zhe Yan
Xiaofei Zhang
Shizhong Yang

Frontiers in Oncology

doi 10.3389/fonc.2022.1051916

3,083 views
1 citation

Original Research

Published on 24 Nov 2022

Establishment and validation of a prognostic nomogram for extrahepatic cholangiocarcinoma

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Fangrui Zhao
Dashuai Yang
Jiahui He
Xianli Ju
Youming Ding
Xiangpan Li

Frontiers in Oncology

doi 10.3389/fonc.2022.1007538

1,718 views
2 citations

Review

Published on 24 Nov 2022

The role of tumor microenvironment reprogramming in primary liver cancer chemotherapy resistance

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Chunyu Zhao
Shanshuo Liu
Feng Gao
Yawen Zou
Zhigang Ren
Zujiang Yu

Frontiers in Oncology

doi 10.3389/fonc.2022.1008902

2,728 views
8 citations

Original Research

Published on 23 Nov 2022

Synergy of Losartan and chemotherapy for patients with cholangiocarcinoma: A propensity score-matched analysis

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Qing Li
Zhenyu Chang
Tianyi Wang
Bing Liu
Ximin Wang
Xin-Yu Ge
Tao Yang
Qu Liu
Wei Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.989080

1,455 views
1 citation

Case Report

Published on 23 Nov 2022

Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Xuexia Liang
Qiaodan Liu
Wei Yao
Shuqin Zhu

Frontiers in Oncology

doi 10.3389/fonc.2022.941454

1,540 views
1 citation

Review

Published on 22 Nov 2022

Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Penghui He
Haifeng Wan
Juan Wan
Hanyu Jiang
Yu Yang
Kunlin Xie
Hong Wu

Frontiers in Oncology

doi 10.3389/fonc.2022.1015527

2,394 views
5 citations

Original Research

Published on 22 Nov 2022

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

He-nan Qin
Zhen Ning
Rui Sun
Chen-xing Jin
Xin Guo
A-man Wang
Ji-wei Liu

Frontiers in Oncology

doi 10.3389/fonc.2022.1003426

3,968 views
4 citations

Original Research

Published on 22 Nov 2022

Integrated systemic analysis of FAM72A to identify its clinical relevance, biological function, and relationship to drug sensitivity in hepatocellular carcinoma

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Qi Zhou
Lingjun Chen
Luo Yang
Haoxiong Zhou
Yan Chen
Yunwei Guo

Frontiers in Oncology

doi 10.3389/fonc.2022.1046473

2,665 views
1 citation

Review

Published on 22 Nov 2022

Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Shilun Wu
Zhuxin Li
Changyu Yao
Shuying Dong
Jun Gao
Shan Ke
Ruhang Zhu
Sen Huang
Shaohong Wang
Li Xu

Frontiers in Oncology

doi 10.3389/fonc.2022.1032746

2,765 views
7 citations

Review

Published on 22 Nov 2022

Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: Update and future perspective

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Xing Ma
Ying Ding
Wenliang Li
Qiang Li
Hui Yang

Frontiers in Oncology

doi 10.3389/fonc.2022.1061065

2,842 views
6 citations

Original Research

Published on 21 Nov 2022

Development and validation of a nomogram to predict liver metastasis for pancreatic ductal adenocarcinoma after radical resection

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Jingshu Tong
Wei Jiang
Shuqi Mao
Shengdong Wu
Caide Lu

Frontiers in Oncology

doi 10.3389/fonc.2022.1040411

1,750 views
1 citation

Original Research

Published on 21 Nov 2022

Bile-volatile organic compounds in the diagnostics of pancreatic cancer and biliary obstruction: A prospective proof-of-concept study

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Ville Teränen
Samuli Nissinen
Antti Roine
Anne Antila
Antti Siiki
Yrjö Vaalavuo
Pekka Kumpulainen
Niku Oksala
Johanna Laukkarinen

Frontiers in Oncology

doi 10.3389/fonc.2022.918539

1,614 views
1 citation

Navigation group

Articles

Emerging current trends and research focus related to pancreatic cancer metabolism: A bibliometric and visualized analysis

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world

The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study

Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial

Establishment and validation of a prognostic nomogram for extrahepatic cholangiocarcinoma

The role of tumor microenvironment reprogramming in primary liver cancer chemotherapy resistance

Synergy of Losartan and chemotherapy for patients with cholangiocarcinoma: A propensity score-matched analysis

Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review

Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis

Integrated systemic analysis of FAM72A to identify its clinical relevance, biological function, and relationship to drug sensitivity in hepatocellular carcinoma

Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research

Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: Update and future perspective

Development and validation of a nomogram to predict liver metastasis for pancreatic ductal adenocarcinoma after radical resection

Bile-volatile organic compounds in the diagnostics of pancreatic cancer and biliary obstruction: A prospective proof-of-concept study